This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A multicenter, open-label, long-term safety extens...
Clinical trial

A multicenter, open-label, long-term safety extension of phase II studies ABE4869G and ABE4955G in patients with mild to moderate alzheimer�s disease

Read time: 1 mins
Last updated:12th Sep 2012
To assess the long-term safety and tolerability of crenezumab administered subcutaneously (SC) every 2 weeks (q2w) or intravenously (IV) every 4 weeks (q4w), in eligible patients with Alzheimer�s disease who participated in Study ABE4869g or ABE4955g and completed the Week 73 study visit, including brain MRI.
Category Value
Study start date 2012-09-12

View full details